Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows in line with its trailing trend

Q1 FY2026 net income of $12.45M (cash outflow) rose 84.0% year over year, behind the +84.6% change in trailing-twelve-month net income. Sequentially, it fell 26.5% from the prior quarter. Over 3 fiscal years it compounded at +27.3% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$52.32M (+33.4%) for the fiscal year ending Dec 2026, a slowdown from the +52.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.45M-26.5% QoQ
Last fiscal yearDec 2025
-$39.22M+52.3% YoY
LTMMar 2026
-$42.72M+84.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.0%+97.3%+13.2 pp
1 year+52.3%+33.4%-18.9 pp
3-year CAGR+27.3%+24.8%-2.6 pp
5-year CAGR-12.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
(39.22M) USD
Year-over-year change
-52.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +84.6% is the 4th highest of 9, against a peer median of +38.6%.
  • Over three fiscal years its annual growth of +27.3% compares with a peer median of +6.8%.
EPRX Competitors
Net Income for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$151.77M USD+296.2%—8550.6%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$69.87M USD+152.1%+61.9%—
TARAProtara Therapeutics, Inc.LTM Mar 2026$63.31M USD+39.4%-4.5%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M USD-16.9%+0.6%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.72M USD+84.6%+27.3%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$35.76M USD+37.8%-13.4%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$32.96M USD———
MDWDMediWound Ltd.LTM Mar 2026$26.1M USD+23.0%+6.8%180.3%
Peer median (excluding EPRX) —+38.6%+6.8%3884.0%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(18.18M)(18.99M)(21.81M)(25.74M)(39.22M)
Depreciation & Amortization88.17K147.89K117.1K171.72K241.68K
Deferred Income Tax00000
Stock-Based Compensation01.43M1.06M3.22M0
Change in Working Capital(167.16K)1.51M4.03M(6.76M)(725.6K)
Accounts Receivables150.92K230.48K(78.09K)(101.39K)(438.64K)
Inventory00000
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(318.07K)(39.96K)3.67M(5.95M)(2.69M)
Other Non-Cash Items6.68M1.5M977.18K(880.5K)10.68M
Operating Cash Flow(11.58M)(14.4M)(15.62M)(29.99M)(29.03M)
Capital Expenditures(341.28K)(235.55K)(55.25K)(104.23K)(598.77K)
Acquisitions (Net)00000
Purchases of Investments(7.12M)(3.27M)000
Sales of Investments013.34M000
Other Investing Activities(3.97M)242029.07K0
Investing Cash Flow(11.42M)9.83M(55.25K)(75.16K)(598.77K)
Debt Repayment9.62M(142.27K)(59.81K)(9.14M)0
Common Stock Issued29.91M10.64M11.96M54.56M77.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(69.33K)306.77K3.97M363.06K0
Financing Cash Flow39.46M10.8M15.87M45.78M77.33M
Effect of Forex Changes(63.69K)(507.4K)618.45K(1.96M)(403.1K)
Net Change in Cash16.4M5.73M811.93K13.76M47.3M
Free Cash Flow(11.92M)(14.63M)(15.68M)(30.1M)(29.63M)

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.